BiotechTube

LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696

Phase 2/3Completed
3 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pediatric Heart Failure

Conditions

Pediatric Heart Failure

Trial Timeline

Nov 3, 2016 → Jan 3, 2022

NCT ID
NCT02678312

About LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696

LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 is a phase 2/3 stage product being developed by Novartis for Pediatric Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT02678312. Target conditions include Pediatric Heart Failure.

What happened to similar drugs?

3 of 19 similar drugs in Pediatric Heart Failure were approved

Approved (3) Terminated (0) Active (16)
✅Boosted AtazanavirBristol Myers SquibbApproved
✅Atazanavir + RitonavirBristol Myers SquibbApproved
✅IgPro10CSLApproved
🔄candsartan cilexetilAstraZenecaPhase 3
🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3
🔄VAL489 + VAL489 matching placeboNovartisPhase 3
🔄Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02678312Phase 2/3Completed

Competing Products

20 competing products in Pediatric Heart Failure

See all competitors
ProductCompanyStageHype Score
RamucirumabEli LillyPhase 1
29
erlotinib + etoposideAstellas PharmaPhase 2
27
Mitoxantrone Hydrochloride Liposome + Irinotecan + VincristineSun PharmaceuticalPhase 1
33
Perampanel Oral Suspension + Perampanel TabletEisaiPhase 2
42
Eribulin MesylateEisaiPhase 1
29
Decitabine + DecitabineEisaiPhase 2
27
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once dailySumitomo PharmaPhase 1
29
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or LinezolidAstraZenecaPhase 2/3
38
candsartan cilexetilAstraZenecaPhase 3
40
Durvalumab / Tremelimumab Combination TherapyAstraZenecaPhase 1/2
36
Rotavirus VaccineMerckPre-clinical
18
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3
40
VAL489 + VAL489 matching placeboNovartisPhase 3
40
EverolimusNovartisPhase 2
35
Corticosteroids + Cyclosporine + mycophenolate mofetilRochePhase 2
27
Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3
40
Blinatumomab for InjectionAmgenPhase 1
25
EtanerceptAmgenPhase 3
40
DenosumabAmgenPhase 3
40